Silk Road Medical, Inc

Equities

SILK

US82710M1009

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
18.9 ^USD	+6.18%		+8.56%	+54.03%

Apr. 02	Silk Road Medical Strengthens TCAR Portfolio with Launch of ENROUTE Transcarotid Neuro Protection System Plus	CI
Mar. 08	North American Morning Briefing : Stock Futures -2-	DJ

Silk Road Medical, Inc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

February 28, 2024 at 04:07 pm EST

Silk Road Medical, Inc reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was USD 47.27 million compared to USD 40.07 million a year ago. Net loss was USD 13.01 million compared to USD 12.61 million a year ago.

Basic loss per share from continuing operations was USD 0.33 compared to USD 0.34 a year ago.

Latest news about Silk Road Medical, Inc

Silk Road Medical Strengthens TCAR Portfolio with Launch of ENROUTE Transcarotid Neuro Protection System Plus	Apr. 02	CI
North American Morning Briefing : Stock Futures -2-	Mar. 08	DJ
Silk Road Medical Inc. and Genesis MedTech Group have signed an exclusive distribution agreement to introduce the TCAR® core products	Mar. 07	CI
Argus Upgrades Silk Road Medical to Buy From Hold, Price Target is $24	Mar. 07	MT
Silk Road Medical Expands TCAR Portfolio with Launch of Tapered Enroute®? Transcarotid Stent System	Mar. 05	CI
Piper Sandler Raises Price Target on Silk Road Medical to $18 From $11, Maintains Neutral Rating	Feb. 29	MT
Transcript : Silk Road Medical, Inc, Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Earnings Flash (SILK) SILK ROAD MEDICAL Reports Q4 Revenue $47.3M, vs. Street Est of $42M	Feb. 28	MT
Silk Road Medical, Inc Provides Revenue Guidance for the Full Year 2024	Feb. 28	CI
Silk Road Medical, Inc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
North American Morning Briefing : S&P 500 Seen -2-	Jan. 22	DJ
Sector Update: Health Care Stocks Steady Late Afternoon	Jan. 19	MT
Silk Road Medical Shares Rise After Upgrade From Stifel	Jan. 19	MT
Stifel Upgrades Silk Road Medical to Buy From Hold, Raises Price Target to $20 From $9	Jan. 19	MT
Transcript : Silk Road Medical, Inc Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 01:30 PM	Jan. 10
Lake Street Initiates Silk Road Medical at Buy Rating With $20 Price Target	Jan. 03	MT
Oppenheimer Adjusts Silk Road Medical Price Target to $25 From $30, Maintains Outperform Rating	Nov. 09	MT
Transcript : Silk Road Medical, Inc, Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
Earnings Flash (SILK) SILK ROAD MEDICAL Reports Q3 Revenue $44.4M, vs. Street Est of $44.3M	Nov. 08	MT
Silk Road Medical, Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Silk Road Medical, Inc Provides Revenue Guidance for the Full Year 2023	Nov. 08	CI
Silk Road Medical Appoints Chas McKhann Chief Executive; Shares Rise	Nov. 02	MT
Silk Road Medical Announces Chief Executive Officer Changes	Nov. 02	CI
North American Morning Briefing : Google Parent's -2-	23-10-25	DJ
Wolfe Research Upgrades Silk Road Medical to Peer Perform From Underperform	23-10-24	MT

Chart Silk Road Medical, Inc

Duration

Period

More charts

Company Profile

Silk Road Medical, Inc. is a medical device company that is focused on reducing the risk of stroke and its impact. The Company has developed an approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. Its product portfolio consists of five single-use components: ENROUTE Transcarotid Neuroprotection System, ENROUTE Transcarotid Stent System, ENHANCE Transcarotid Peripheral Access Kit, ENROUTE 0.014'' Guidewire and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter. It manufactures ENROUTE NPS and ENROUTE NPS PLUS, or its ENROUTE NPS products, at its facilities in Sunnyvale, California and Plymouth, Minnesota. These facilities provide an aggregate of over 35,000 square feet of space for its production and distribution operations.

Sector

Medical Equipment, Supplies & Distribution

Calendar

04:05pm - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Silk Road Medical, Inc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

18.9 USD

Average target price

18.43 USD

Spread / Average Target

-2.49%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
SILK ROAD MEDICAL, INC	+54.03%	745M
ABBOTT LABORATORIES	-2.54%	186B
MEDTRONIC PLC	-1.85%	107B
BECTON, DICKINSON AND COMPANY	-4.26%	67.44B
DEXCOM, INC.	+1.39%	50.03B
CENCORA, INC.	+16.82%	47.81B
HOYA CORPORATION	+4.79%	41.03B
METTLER-TOLEDO INTERNATIONAL, INC.	+3.49%	26.85B
WEST PHARMACEUTICAL SERVICES, INC.	+0.65%	25.82B
TERUMO CORPORATION	+16.55%	24.74B

Other Medical Equipment, Supplies & Distribution